JP2010516693A - Kit阻害剤に対して獲得した抵抗性を有する癌の処置 - Google Patents
Kit阻害剤に対して獲得した抵抗性を有する癌の処置 Download PDFInfo
- Publication number
- JP2010516693A JP2010516693A JP2009546528A JP2009546528A JP2010516693A JP 2010516693 A JP2010516693 A JP 2010516693A JP 2009546528 A JP2009546528 A JP 2009546528A JP 2009546528 A JP2009546528 A JP 2009546528A JP 2010516693 A JP2010516693 A JP 2010516693A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- amino acid
- stage
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 86
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 201000011510 cancer Diseases 0.000 title claims description 53
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 48
- 230000035772 mutation Effects 0.000 claims description 74
- 238000012217 deletion Methods 0.000 claims description 33
- 230000037430 deletion Effects 0.000 claims description 33
- 125000000539 amino acid group Chemical group 0.000 claims description 32
- 230000000306 recurrent effect Effects 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 21
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 19
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 18
- -1 3-trifluoromethylphenyl Chemical group 0.000 claims description 17
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 17
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 17
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 14
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 11
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 101150068332 KIT gene Proteins 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 229960003685 imatinib mesylate Drugs 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 8
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 8
- 229960002411 imatinib Drugs 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 102220197933 rs1057519761 Human genes 0.000 claims description 7
- 102200076875 rs121913514 Human genes 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 7
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 6
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 6
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 6
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 6
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 6
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 102220197813 rs1057519710 Human genes 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 4
- 108700024394 Exon Proteins 0.000 claims description 4
- 206010064571 Gene mutation Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 4
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 102200076818 rs121913517 Human genes 0.000 claims description 4
- 102220197808 rs121913523 Human genes 0.000 claims description 4
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 4
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 102220197814 rs1057519711 Human genes 0.000 claims description 3
- 102220198452 rs1057520032 Human genes 0.000 claims description 3
- 102220198373 rs1057520034 Human genes 0.000 claims description 3
- 102220197797 rs121913235 Human genes 0.000 claims description 3
- 102220197806 rs121913513 Human genes 0.000 claims description 3
- 102200076819 rs121913517 Human genes 0.000 claims description 3
- 102220197803 rs121913521 Human genes 0.000 claims description 3
- 102200076877 rs121913682 Human genes 0.000 claims description 3
- 102220215734 rs769701248 Human genes 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- GFZFAQOKWZGMQL-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)phenyl]-3-oxopropanenitrile Chemical compound FC(F)(F)C1=CC(C(=O)CC#N)=CC(C(F)(F)F)=C1 GFZFAQOKWZGMQL-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000004891 B-cell adult acute lymphocytic leukemia Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000005485 Thrombocytosis Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 208000030224 brain astrocytoma Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000004018 childhood brain stem glioma Diseases 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000029503 grade II meningioma Diseases 0.000 claims description 2
- 208000030316 grade III meningioma Diseases 0.000 claims description 2
- 230000001096 hypoplastic effect Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000003175 male breast cancer Diseases 0.000 claims description 2
- 208000010907 male breast carcinoma Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 210000001167 myeloblast Anatomy 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 208000021284 ovarian germ cell tumor Diseases 0.000 claims description 2
- 208000010918 peritoneal neoplasm Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102220197900 rs121913516 Human genes 0.000 claims 2
- 102220197801 rs121913521 Human genes 0.000 claims 2
- 102220108317 rs149325238 Human genes 0.000 claims 2
- 102200143072 rs9885672 Human genes 0.000 claims 2
- QCCFHYDJJVYCFZ-UHFFFAOYSA-N 7-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=NN=C2C1=CN=CN2C(C)(C)C QCCFHYDJJVYCFZ-UHFFFAOYSA-N 0.000 claims 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 208000028191 childhood central nervous system germ cell tumor Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000006971 mastocytoma Diseases 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000003826 tablet Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 229920002785 Croscarmellose sodium Polymers 0.000 description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 14
- 239000007962 solid dispersion Substances 0.000 description 14
- 229960001681 croscarmellose sodium Drugs 0.000 description 13
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100039064 Interleukin-3 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000003711 photoprotective effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- ZQHJPIPGBODVTG-UHFFFAOYSA-N 4-(4-Amino-3-fluorophenoxy)-N-methyl-2-pyridinecarboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(N)=CC=2)=C1 ZQHJPIPGBODVTG-UHFFFAOYSA-N 0.000 description 2
- MNPLTKHJEAFOCA-UHFFFAOYSA-N 4-amino-3-fluorophenol Chemical compound NC1=CC=C(O)C=C1F MNPLTKHJEAFOCA-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920003114 HPC-L Polymers 0.000 description 2
- 229920003115 HPC-SL Polymers 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229940008309 acetone / ethanol Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical class OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- ZXUJWPHOPHHZLR-UHFFFAOYSA-N 1,1,1-trichloro-2-fluoroethane Chemical compound FCC(Cl)(Cl)Cl ZXUJWPHOPHHZLR-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical class C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical compound CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- UHFMDUIMUVSXJC-UHFFFAOYSA-N 1-hydroxy-2h-pyridine Chemical compound ON1CC=CC=C1 UHFMDUIMUVSXJC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CSSGKHVRDGATJL-UHFFFAOYSA-N 3-fluoro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(F)=C1 CSSGKHVRDGATJL-UHFFFAOYSA-N 0.000 description 1
- PAZXTVFHRWRCLP-UHFFFAOYSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 PAZXTVFHRWRCLP-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- BGVBBMZMEKXUTR-UHFFFAOYSA-N 4-chloro-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC(Cl)=CC=N1 BGVBBMZMEKXUTR-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100398281 Homo sapiens KIT gene Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- DLGYNVMUCSTYDQ-UHFFFAOYSA-N azane;pyridine Chemical compound N.C1=CC=NC=C1 DLGYNVMUCSTYDQ-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FIUGIHSMYBTREC-UHFFFAOYSA-N chembl166390 Chemical compound C1=CC(C)=CC=C1N1C(=N)C(C=NN2)=C2N(C(C)(C)C)C1 FIUGIHSMYBTREC-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FNMTVMWFISHPEV-AATRIKPKSA-N dipropan-2-yl (e)-but-2-enedioate Chemical compound CC(C)OC(=O)\C=C\C(=O)OC(C)C FNMTVMWFISHPEV-AATRIKPKSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000010336 energy treatment Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000006543 gametophyte development Effects 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200076883 rs121913506 Human genes 0.000 description 1
- 102200076881 rs121913507 Human genes 0.000 description 1
- 102220019900 rs276174902 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000024662 testicular seminoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000005290 uterine carcinosarcoma Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
オメガカルボキシアリールジフェニル尿素はWO00/42012(2000年7月20日発行)およびWO00/41698(2000年7月20日発行)に記載されており、ここでは4−{4−〔3−(4−クロロー3−トリフルオロメチルフェニル)ウレイド〕−3−フルオロフェノキシ}ピリジン−2−カルボキシ酸メチルアミドと呼ぶジフェニル尿素、DASTはWO05/009961(2005年2月3日発行)に開示され、そしてraf,VEGFR−2,p38およびPDGFRキナーゼの強力な阻害剤として記載されている。これらの酵素は癌を含む高増殖病の処置のために関心ある分子標的である。DASTの固体分散体はWO06/026500(2006年3月9日発行)に記載されている。
1H−NMR(DMSO−d6)4.38(s,2H),6.29−6.35(m,1H),6.41(dd,J=2.5,12.7,1H),6.52−6.62(m,1H),8.76(s,1H)
1H−NMR(DMSO−d6)2.78(d,J=4.9,3H),7.03−7.08(m,1H),7.16(dd,J=2.6,5.6,1H),7.32(dd,J=2.7,11.6.1H),7.39(d,J=2.5,1H),7.60(s,2H),8.07−8.18(m,2H),8.50(d,J=5.7,1H),8.72(s,1H),8.74−8.80(m,1H),9.50(s,1H),;MS(HPLC/ES)483.06m/z=(M+1)
遊離塩基の形の実施例1の化合物(2.0g)を無水テトラヒドロフラン(15mL)に溶解し、そして4M HCl/ジオキサン(過剰)を加えた。溶液を次に減圧濃縮し、灰白色固体2.32gを得た。この粗製塩を熱エタノール(125mL)に溶解し、活性炭を加え、混合物を15分間還流へ加熱した。熱懸濁液をセライト521のパッドを通して濾過し、室温へ冷却した。フラスコをフリーザー中に一夜置いた。結晶性固体を吸引濾過して集め、エタノール次にヘキサンで洗い、空気乾燥した。母液を濃縮し、フリーザー中で一夜結晶化を許容した。固体の2番目のクロップを集め、最初のクロップと合併した。無色の塩を60℃でオーブン中2日間減圧乾燥した。得られた塩酸塩の収量は1.72g(79%)であった。融点215℃
元素分析:
計算値 実測値
C 48.57 48.68
H 3.11 2.76
N 10.79 10.60
Cl 13.65 13.63
F 14.63 14.88
遊離塩基としての実施例1の化合物(2.25g)をエタノール(100mL)に溶解し、メタンスルホン酸のストック溶液(過剰)を加えた。溶液を次に減圧濃縮し、黄色オイルを得た。エタノールを加え、くり返し濃縮し、灰白色固体2.41gを得た。粗製塩を熱エタノール(〜125mL)に溶解し、結晶化のためゆっくり冷却した。室温に達した後、フラスコを一夜フリーザー中に置いた。無色結晶性物質を吸引濾過により集め、フイルターケーキをエタノール、次いでヘキサンで洗い、風乾し、物質2.05gを得た。このものは60℃で一夜真空オーブン中で乾燥した。融点231℃
元素分析:
計算値 実測値
C 45.64 45.34
H 3.31 3.08
N 9.68 9.44
Cl 6.12 6.08
F 13.13 13.42
S 5.54 5.59
遊離塩基として実施例1の化合物(2.25g)をエタノール(50mL)に懸濁し、エタノール(50mL)中のベンゼンスルホン酸(0.737g)を加えた。混合物を激しくかきまぜながら加熱した。すべての原料が溶解し、赤色溶液を与えた。この溶液を室温へ冷却し、フラスコをこすった。結晶形成は遅く、いくらかの種晶を溶液へ加え、フラスコをフリーザー中に一夜置いた。灰色がかった黄褐色の固体がフラスコ中に生成した。これを砕き、吸引濾過により集めた。固体をエタノール、次にヘキサンで洗い、風乾した。秤量した生成物2.05g,69%収率。融点213℃
元素分析:
計算値 実測値
C 50.59 50.24
H 3.30 3.50
N 8.74 8.54
F 11.86 11.79
Cl 5.53 5.63
S 5.00 5.16
キャップしてないバイアル中で、塩基として実施例1の化合物1部と、ポリビニルピロリドン(PVP−25/Kollidon 25)とを混合し、すべての粉末が溶液になるまでアセトンとエタノール1:1混合物の十分な量に溶解した。キャップしてないバイアルを40℃にセットした真空オーブン中に入れ、少なくとも24−48時間乾燥した。
遊離塩基として実施例1の化合物1部と、ポリビニルピロリドン(PVP−25/Kollidon 25)3部を80:20アセトン/エタノール混液(w/w)30部に溶解した。ロータリ真空エバポレーターを用い、溶媒を70℃で除去した。乾燥残渣をエバポレーターフラスコから除去し、篩分(630μm)した。
塩基として実施例1の化合物1部と、PVP7部を80:20アセトン/エタノール混合物(w/w)30部に溶解した。ロータリ真空エバポレーターを用いて溶媒を70℃で除去した。乾燥した残渣をエバポレーターフラスコから取り出し、篩分(630μm)した。
遊離塩基として実施例1の化合物2部をマルチトール1部およびHPC−M7部と混合した。混合物を実験室二軸スクリュー押出機を用いて160−200℃の温度において押出した。押出した材料をカットし、その後実験室衝撃ミルを用いて粉砕した。得られた粉末はそのまま、または小袋、カプセルまたは錠剤に製剤することができる。
塩基として式Iの化合物0.4kgと、PVP25 1.2kgのアセトン6.4kgとエタノール1.6kgの混合物の溶液を調製した。流動床真空グラニュレーターを用いてこの溶液をクロスカルメロースナトリウム1.6kgの粉末ベッドに60−70℃の温度にいてスプレーした。乾燥後生成物を篩分(1mm)した。この顆粒はそのまま、または例えば小袋カプセルまたは錠剤に製剤することができる。
この物質は、溶液がデンプングリコール酸ナトリウムタイプA(Expolatab)1.6kgの粉末床にスプレーされることを除き、実施例9に記載したのと同様に調製された。
アセトン6.4kgとエタノール1.6kgの混液中の塩基として式Iの化合物0.4kgとPVP25 1.6kgの溶液を調製した。流動床真空グラニュレータを用いて、この溶液をクロスカルメロースナトリウム2kgの粉末床に60−70℃の温度においてスプレーした。乾燥後生成物を篩分(1mm)した。この顆粒はそのまま使用することができ、または例えば小袋、カプセルまたは錠剤に製剤することができる。
この物質は、溶液をクロスカルメロースナトリウム1kgと微結晶セルロース1kgよりなる粉末床にスプレーしたことを除き、実施例11に記載したのと同様に調製された。
アセトン20kg中の塩基として式Iの化合物0.4kgとHPC−SL 1.6kgの溶液を調製した。流動床真空グラニュレーターを用いて、この溶液を40−60℃の温度においてクロスカルメロース2kgの粉末床にスプレーした。乾燥後生成物を篩分(1mm)した。この顆粒はそのまま使用することができ、または例えば小袋、カプセルまたは錠剤に製剤することができる。
アセトン28kg中の塩基として式Iの化合物0.4kgとHPC−L 1.6kgの溶液を調製した。流動床真空グラニュレーターを用いて、この溶液を40−60℃の温度においてクロスカルメロースナトリウネ2kgの粉末床にスプレーした。乾燥後生成分を篩分(1mm)した。この顆粒はそのまま使用でき、または例えば小袋、カプセルまたは錠剤に製剤することができる。
実施例11の顆粒をローラーコンパクト化し、3および1mmにスクリーンした。その後コンパクト化した顆粒をクロスカルメロースナトリウム0.54kgと、コロイダル無水シリカ24gと、そしてステアリン酸マグネシウム36gとブレンドした。この圧縮用ブレンドを式Iの化合物20,50および100mgを含む錠剤に回転打錠機で圧縮した。錠剤は光保護のためフィルムコーティングすることができる。
実施例12の顆粒をローラーコンパクト化し、3および1mmにスクリーンした。その後コンパクト化した顆粒をクロスカルメロースナトリウム0.54kgと、コロイダル無水シリカ24gと、そしてステアリン酸マグネシウム36gとブレンドした。この圧縮用ブレンドを式Iの化合物20,50および100mgを含む錠剤に回転打錠機で圧縮した。錠剤は光保護のためフィルムコーティングすることができる。
アセトン6.4kgとエタノール1.6gの混液中の塩基として0.4kgの式Iの化合物と1.2kgのPVP25溶液を調製した。流動床真空グラニュレーターを用いて、この溶液をクロスカルメロースナトリウム0.8kgと微結晶セルロース0.8kgよりなる粉末床に60−70℃の温度においてスプレーした。乾燥後生成物を篩分(1mm)した。この顆粒をローラーコンパクト化し、そして3および1mmにスクリーンした。その後コンパクト化した顆粒をクロスカルメロースナトリウム1.34gと、コロイダル無水シリカ24gと、ステアリン酸マグネシウム36gとブレンドした。この圧縮用ブレンドを回転打錠機で式Iの化合物20,50および100mgを含む錠剤に圧縮した。錠剤は光保護のためフィルムコーティングすることができる。
c−KIT発現Ba/F3細胞ラインの発生
アミノ酸残基557−558を除去したエクソン11に欠失を有する全長ヒト−c−KITをコードするcDNAを哺乳類発現ベクターpClneo(Promega)中にリゲートした。エクソン11欠失突然変更細胞のImatinib(Gleonvec)抵抗性変種を発生させる。すべての突然変異はDNAシーケンシングによって確認した。
このアッセイは細胞増殖/生存性のマーカーとして細胞ATPを利用する。第1日に、Ba/F3細胞を1mg/mL G418を含むRPMI培地中の10%FBS中で10,000細胞/ウエルに96ウエル皿(Costar 3603)にプレートした。0.6から10,000nMの範囲の最終濃度を与えるように8ポイント投与量レスポンスのための10×において同じ培地中に累進希釈したテスト化合物を細胞へ添加した。プレートを次に37℃で3日間5%CO2インキュベーター中でインキュベートした。72時間後、溶解/ルシフェラーゼ試薬(CellTiter−Glo,Promega G7573)を各ウエルへ添加した。細胞はその後室温で5分間シェーカー上でインキュベートされ、そしてルミネセンスがビクター5(パーキンエルマー)分光光度計上で測定された。発育阻害はアッセイプレート上の処置対未処置ルミネセンス信号を比較することによって測定され、細胞増殖の化合物による阻害のIC50分析はAnalyze5社内ソフトウエアを用いて分析された。種々のc−KIT発現Ba/F3細胞ラインにおけるImatinib(Gleevec)およびNexavarについて得られたIC50値は表1に要約されている。IC50値は少なくとも3実験から計算された平均値である。
Claims (29)
- 癌が以下のKIT阻害剤の一つに対して抵抗性を獲得している請求項1の方法:
imatinibメシレート,imatinibメシレートの誘導体、imatinibメシレートの塩、PP1(4−アミノ−5−(4−メチルフェニル−7−(t−ブチル)ピラゾロ〔3,4−d〕ピリミジン);MLN518(CT53518);PD180970;SU112481;SU5416;SU5414;SU6597;SU6663またはSU6561 - 前記癌は、悪性胃腸間質腫瘍(GIST)、良性胃腸間質腫瘍(GIST)、腸管の間葉腫瘍、慢性骨髄性白血病(CML)、肥満細胞腫瘍、SCLC、胚芽細胞腫瘍、乳癌、および/または神経芽腫の一つまたは二つ以上である請求項1の方法。
- 癌がimatinibメシレートに対して抵抗性を獲得している請求項1の方法。
- 前記癌の前記獲得した抵抗性は、一次腫瘍において突然変異したKIT遺伝子の二次突然変異に関連している請求項1の方法。
- 前記二次突然変異はキナーゼ触媒ドメインにある請求項5の方法。
- 突然変異はエクソン13,14および/または17中にある請求項5の方法。
- 突然変異は残基654,670,716,816,820,822および823にある請求項5の方法。
- 突然変異は残基650−654にある請求項5の方法。
- 突然変異は残基670−674にある請求項5の方法。
- 突然変異は残基816−824にある請求項5の方法。
- 二次突然変異は、V654A(エクソン13)、T6701(エクソン14)、T670E,D716N,S709F(エクソン14)、D816G,D816E(エクソン17)、D820E,D820Y,D820G,N822K,Y823D(エクソン17)、またはそのような位置または隣接位置における欠失および他のアミノ酸置換の一または二以上である請求項5の方法。
- 二次突然変異は、
i)アミノ酸残基557−558の欠失;
ii)アミノ酸残基551−555の欠失;
iii)アミノ酸残基550−558の欠失;
iv)アミノ酸残基559−560の欠失;
v)アミノ酸残基557−561の欠失;
vi)アミノ酸残基554−558の欠失;
vii)アミノ酸残基552−557の欠失;
viii)V559D,V559AまたはV559Gを含む、残基559における突然変異;
ix)V560D,V560EまたはV560Gを含む、残基560における突然変異;
x)W557S単独、またはアミノ酸552−556の欠失との組合せ;
xi)W557Rを含む、アミノ酸残基557における突然変異;および
xii)L576Pを含む、アミノ酸残基576における突然変異;
の一または二以上である請求項5の方法。 - 二次突然変異は残基557−558の欠失と、そして以下の突然変異;V654A,T670I,D820Y,N822KまたはY823Dの少なくとも一つである請求項5の方法。
- 一次腫瘍中の前記一次および/または二次KIT遺伝子突然変異は、KITチロシンキナーゼ阻害剤に対する前記癌の抵抗性に関連している請求項15の方法。
- 前記二次突然変異はキナーゼ触媒ドメインにある請求項15の方法。
- 突然変異はエクソン13,14および/または17中にある請求項15の方法。
- 突然変異は残基654,670,716,816,820,822および823にある請求項15の方法。
- 突然変異は残基650−654にある請求項15の方法。
- 突然変異は残基670−674にある請求項15の方法。
- 突然変異は残基816−824にある請求項15の方法。
- 二次突然変異は、V654A(エクソン13)、T6701(エクソン14)、T670E,D716N,S709F(エクソン14)、D816G,D816E(リクソン17)、D820E,D820Y,D820G,N822K,Y823D(エクソン17)、またはそのような位置または隣接位置における欠失および他のアミノ酸置換の一または二以上である請求項15の方法。
- 二次突然変異は、
i)アミノ酸残基557−558の欠失;
ii)アミノ酸残基551−555の欠失;
iii)アミノ酸残基550−558の欠失;
iv)アミノ酸残基559−560の欠失;
v)アミノ酸残基557−561の欠失;
vi)アミノ酸残基554−558の欠失;
vii)アミノ酸残基552−557の欠失;
viii)V559D,V559AまたはV559Gを含む、残基559における突然変異;
ix)V560D,V560EまたはV560Gを含む、残基560における突然変異;
x)W557S単独、またはアミノ酸552−556の欠失との組合せ;
xi)W557Rを含む、アミノ酸残基557における突然変異;および
xii)L576Pを含む、アミノ酸残基576における突然変異;
の一または二以上である請求項15の方法。 - 二次突然変異は残渣557−558の欠失と、そして以下の突然変異;V654A,T670I,D820Y,N822KまたはY823Dの少なくとも一つである請求項15の方法。
- 処置される癌は、加速期慢性骨髄性白血病;急性赤血球白血病;急性リンパ芽球白血病;緩解期急性リンパ芽球白血病;急性リンパ球白血病;急性単芽球白血病;急性骨髄性白血病;急性骨髄白血病;前立腺腺癌;頭頸部のアデノイドのう胞性癌;進行した胃腸間質腫瘍;原因不明骨髄腫;骨幹端炎;退生稀突起膠腫;星状細胞腫;B細胞成人急性リンパ芽球白血病;芽期慢性骨髄性白血病骨転移;脳腫瘍;乳癌;中枢神経系癌;小児急性リンパ芽球白血病;緩解期小児急性リンパ芽球白血病;小児中枢神経系胚芽細胞腫瘍;小児慢性骨髄性白血病;小児軟組織肉腫;脊索腫;慢性好酸性白血病(CEL);慢性特発性骨髄線維症;慢性骨髄性白血病;慢性骨髄単球白血病;慢性期慢性骨髄性白血病;結腸癌;結直腸癌;皮膚線維肉腫;隆起性皮膚線維肉腫(DFSP);類腱腫;好酸球増加症;流行性カポジ肉腫;本質的血小板血症;Ewingファミリ腫瘍;延長段階小細胞肺癌;ファロピアンチューブ癌;家族性高好酸球増加症;線維肉腫;胃腺癌;胃腸新生物;胃腸間質腫瘍;膠芽腫;グリオーム;神経膠肉腫;グレードI髄膜腫;グレードII髄膜腫;グレードIII髄膜腫;造血リンパ癌;高グレード小児脳星状細胞腫;過多好酸性血病症候群;特発性肺線維症;L1成人急性リンパ芽球白血病、L2成人急性リンパ芽球白血病;急性リンパ球白血病L2;慢性骨髄白血病;慢性期骨髄白血病;肝障害および新生物;肺病;慢性骨髄白血病のリンパ様胚芽期;男性乳癌;悪性線維組織球腫;肥満細胞腫;髄膜血管細胞腫;髄膜腫;転移癌;転移性固形腫瘍;骨髄線維症;慢性期骨髄白血病;骨髄化生;好酸性血症を有する骨髄増殖障害(MPD);神経芽腫;非T非B小児急性リンパ芽球白血病;稀突起膠腫;骨肉腫;卵巣胚芽細胞腫瘍;卵巣低悪性可能性腫瘍;卵巣新生物;膵臓癌;骨髄新生物;腹腔癌;腹腔新生物;フィラデルフィア染色体陽性急性リンパ球白血病;骨髄芽発症にあるフィラデルフィア陽性慢性骨髄白血病;多血症ベラ;肺線維症;再発成人脳腫瘍;再発性成人軟組織肉腫;再発性乳癌;再発性結腸癌;再発性食道癌;再発性胃癌;再発性多形態膠芽腫(GBM);再発性カポジ肉腫;再発性黒色腫;再発性メルケル細胞癌;再発性卵巣上皮癌;再発性膵臓癌;再発性前立腺癌;再発性直腸癌;再発性唾液腺癌;再発性小細胞肺癌;Ewingファミリの再発性腫瘍;再発性子宮肉腫;再発性慢性骨髄性白血病;リュウマチ性関節炎;唾液腺アデノイドのう胞性癌;肉腫;小細胞肺癌;ステージII黒色腫;ステージIIメルケル細胞癌;ステージIII成人軟組織肉腫;ステージIII食道癌;ステージIIIメルケル細胞癌;ステージIII卵巣上皮癌;ステージIII膵臓癌;ステージIII唾液腺癌;ステージIIIB乳癌;ステージIIIC乳癌;ステージIV成人軟組織肉腫;ステージIV乳癌;ステージIV結腸癌;ステージIV食道癌;ステージIV胃癌;ステージIV黒色腫;ステージIV卵巣上皮癌;ステージIV前立腺癌;ステージIV直腸癌;ステージIV唾液腺癌;ステージIVA膵臓癌;ステージIVB膵臓癌;全身性肥満細胞症;T細胞小児急性リンパ芽球白血球;睾丸癌;甲状腺癌;切除不能または転移性悪性胃腸間質腫瘍(GIST);特定されない成人固形腫瘍;未処置小児脳幹膠腫;子宮カルシノ肉腫;および子宮肉腫である請求項1または27の方法。
- imatinibに対して抵抗性を獲得した対象の癌を処置する方法であって、前記対象へDASTの有効量を投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88572807P | 2007-01-19 | 2007-01-19 | |
US60/885,728 | 2007-01-19 | ||
PCT/US2008/051406 WO2008089389A2 (en) | 2007-01-19 | 2008-01-18 | Treatment of cancers with acquired resistance to kit inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010516693A true JP2010516693A (ja) | 2010-05-20 |
JP5885012B2 JP5885012B2 (ja) | 2016-03-15 |
Family
ID=39400430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009546528A Active JP5885012B2 (ja) | 2007-01-19 | 2008-01-18 | Kit阻害剤に対して獲得した抵抗性を有する癌の処置 |
Country Status (6)
Country | Link |
---|---|
US (4) | US8680124B2 (ja) |
EP (1) | EP2129376B1 (ja) |
JP (1) | JP5885012B2 (ja) |
CA (1) | CA2675980C (ja) |
ES (1) | ES2429107T3 (ja) |
WO (1) | WO2008089389A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
ES2387812T3 (es) * | 2004-09-29 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | Forma termodinámicamente estable del tosilato BAY 43-9006 |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP2129376B1 (en) * | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
CN102190616B (zh) * | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
CA2796744A1 (en) * | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US20130183268A1 (en) | 2010-07-19 | 2013-07-18 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
CN104250227A (zh) * | 2013-06-29 | 2014-12-31 | 广东东阳光药业有限公司 | 瑞戈非尼新晶型及其制备方法 |
JP6768639B2 (ja) * | 2014-05-23 | 2020-10-21 | セルデックス セラピューティクス,インコーポレーテッド | 好酸球又はマスト細胞関連障害の治療 |
CN104910067A (zh) * | 2015-03-05 | 2015-09-16 | 南京工业大学 | 一锅法合成瑞戈非尼的方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526008A (ja) * | 2001-12-04 | 2005-09-02 | オニックス ファーマシューティカルズ,インコーポレイティド | 癌を処置するためのraf−mek−erk経路インヒビター |
JP2006519182A (ja) * | 2003-02-28 | 2006-08-24 | バイエル ファーマシューティカルス コーポレーション | 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な2−オキソ−1,3,5−パーヒドロトリアザピン誘導体 |
JP2006528196A (ja) * | 2003-07-23 | 2006-12-14 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
JP2006528986A (ja) * | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
JP2009514910A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 肺高血圧を処置するためのジアリールウレア |
JP2010516692A (ja) * | 2007-01-19 | 2010-05-20 | バイエル・ヘルスケア・エルエルシー | 化学療法剤に対し抵抗性を有する癌の処置 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ES2426938T3 (es) | 2001-12-03 | 2013-10-25 | Bayer Healthcare Llc | Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos |
US20080108672A1 (en) | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
CN1318404C (zh) | 2002-02-11 | 2007-05-30 | 拜耳制药公司 | 作为激酶抑制剂的芳基脲类化合物 |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
US20060234931A1 (en) | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
GB0408406D0 (en) | 2004-04-15 | 2004-05-19 | Unilever Plc | Antiperspirant or deodorant compositions |
US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2008542214A (ja) | 2005-05-27 | 2008-11-27 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 疾患を処置するためのジアリールウレア化合物およびpi3、aktキナーゼまたはmtor阻害剤(ラパマイシン)を含む組合せ治療 |
WO2006125539A2 (en) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
PL1948176T3 (pl) | 2005-11-10 | 2011-05-31 | Bayer Schering Pharma Ag | Diarylomoczniki do leczenia nadciśnienia płucnego |
CA2629863A1 (en) | 2005-11-14 | 2007-05-24 | Scott Wilhelm | Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors |
WO2007059155A1 (en) * | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
MX2008006979A (es) | 2005-12-01 | 2009-01-14 | Bayer Healthcare Llc | Compuestos de urea utiles en el tratamiento contra el cancer. |
EP2094268A2 (en) | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP2081902A1 (en) | 2006-11-09 | 2009-07-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
CA2669158A1 (en) | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
EP2129376B1 (en) * | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
-
2008
- 2008-01-18 EP EP08727888.3A patent/EP2129376B1/en active Active
- 2008-01-18 WO PCT/US2008/051406 patent/WO2008089389A2/en active Application Filing
- 2008-01-18 ES ES08727888T patent/ES2429107T3/es active Active
- 2008-01-18 JP JP2009546528A patent/JP5885012B2/ja active Active
- 2008-01-18 CA CA2675980A patent/CA2675980C/en active Active
- 2008-01-18 US US12/523,652 patent/US8680124B2/en active Active
-
2014
- 2014-03-05 US US14/197,940 patent/US20150018393A1/en not_active Abandoned
-
2017
- 2017-01-24 US US15/414,172 patent/US20170165242A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/031,058 patent/US20180311220A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526008A (ja) * | 2001-12-04 | 2005-09-02 | オニックス ファーマシューティカルズ,インコーポレイティド | 癌を処置するためのraf−mek−erk経路インヒビター |
JP2006519182A (ja) * | 2003-02-28 | 2006-08-24 | バイエル ファーマシューティカルス コーポレーション | 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な2−オキソ−1,3,5−パーヒドロトリアザピン誘導体 |
JP2006528986A (ja) * | 2003-05-20 | 2006-12-28 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
JP2007511203A (ja) * | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
JP2006528196A (ja) * | 2003-07-23 | 2006-12-14 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
JP2009514910A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 肺高血圧を処置するためのジアリールウレア |
JP2010516692A (ja) * | 2007-01-19 | 2010-05-20 | バイエル・ヘルスケア・エルエルシー | 化学療法剤に対し抵抗性を有する癌の処置 |
Also Published As
Publication number | Publication date |
---|---|
US20170165242A1 (en) | 2017-06-15 |
EP2129376A2 (en) | 2009-12-09 |
WO2008089389A3 (en) | 2009-01-08 |
US20100267777A1 (en) | 2010-10-21 |
US8680124B2 (en) | 2014-03-25 |
CA2675980A1 (en) | 2008-07-24 |
US20180311220A1 (en) | 2018-11-01 |
CA2675980C (en) | 2016-06-21 |
JP5885012B2 (ja) | 2016-03-15 |
WO2008089389A2 (en) | 2008-07-24 |
EP2129376B1 (en) | 2013-07-24 |
US20150018393A1 (en) | 2015-01-15 |
ES2429107T3 (es) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5885012B2 (ja) | Kit阻害剤に対して獲得した抵抗性を有する癌の処置 | |
US20100144749A1 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
JP2010516692A (ja) | 化学療法剤に対し抵抗性を有する癌の処置 | |
JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
US10118910B2 (en) | Benzothiophene-based selective estrogen receptor downregulators | |
WO2007059155A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
WO2013184119A1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
MX2008014953A (es) | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. | |
WO2014082578A1 (zh) | 杂芳基炔烃化合物及其应用 | |
TW200916458A (en) | Heterocyclic compounds and methods of use thereof | |
WO2012073184A1 (en) | Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases | |
WO2016025648A1 (en) | Combinations of an erk inhibitor and a raf inhibitor and related methods | |
RU2652992C2 (ru) | Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения | |
TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
US20230100235A1 (en) | Anticancer agent composition | |
TW202313050A (zh) | 組合療法 | |
CN114456166A (zh) | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 | |
JP7096333B2 (ja) | プロテインキナーゼに対する阻害活性を有するチエノ[3,2-d]ピリミジン化合物 | |
WO2016025652A1 (en) | Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods | |
KR20230146655A (ko) | Mek 억제제로서의 3,4-디히드로-2,7-나프티리딘-1,6(2h,7h)-디온 | |
KR20240043704A (ko) | Mek 억제제로서의 3,4-디히드로-2,7-나프티리딘-1,6(2h,7h)-디온 | |
CN114853746A (zh) | 甲酰胺类化合物、其制备方法及其在医药上的应用 | |
CN116354960A (zh) | Shp2磷酸酶抑制剂 | |
WO2016025656A1 (en) | Combinations of an erk inhibitor and a pi3k inhibitor or dual pi3k/tor inhibitor and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130820 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140214 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151007 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5885012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |